longbridge

PRME

----

Prime Medicine Inc. (PRME) maintained an increase of over 32.4%, once achieving the best intraday performance since September 2024, with a cumulative increase of approximately 67.3% over the last five trading days, attracting investor interest with its gene editing technology

Wallstreetcn

Prime Medicine Inc. (PRME) maintained a gain of over 32.4%, once achieving its best intraday performance since September 2024, with a cumulative increase of approximately 67.3% over the last five trading days, attracting investor interest with its gene editing technology

Source: Wallstreetcn The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.

© 2026 Longbridge｜Terms of ServicePrivacy Policy